GHRP-6 vs IGF-1 LR3

Ghrelin receptor agonist; stimulates pituitary GH release and increases appetite via hypothalamic ghrelin pathways

GHRP-6 (growth hormone-releasing peptide 6) is a synthetic hexapeptide GH secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) in pituitary somatotrophs and the hypothalamus, stimulating GH release through a mechanism that is synergistic with but distinct from endogenous growth hormone-releasing hormone (GHRH). Like other GHRP-class peptides, it engages hypothalamic arcuate nucleus circuits to potentiate GHRH-driven GH pulses and partially suppress somatostatin inhibitory tone; it was among the first GHRP-class compounds characterized pharmacologically and has been used extensively as a research tool for probing the GH secretory axis. Clinical studies have demonstrated dose-dependent GH release following GHRP-6 administration in human subjects, and the GHRP pharmacological class has been characterized across multiple studies documenting pituitary and hypothalamic mechanisms of action. GHRP-6 is not FDA-approved for any indication; it has been studied as a pharmacological tool and provocative GH stimulation agent but has not been evaluated for safety or efficacy in performance enhancement or muscle building outside research protocols. GHRP-6 dosage in research contexts: studies have used subcutaneous and intravenous doses typically in the range of 100–300 mcg per injection. In research protocols, GHRP-6 is often administered 2–3 times daily — before meals, before training, or before sleep — to leverage the body's natural GH pulse windows. GHRP-6 produces a pronounced appetite stimulation effect (a direct ghrelin-mimetic consequence) that is stronger than what is observed with more selective GHRPs such as ipamorelin; this characteristic is relevant to research contexts studying GH secretion alongside energy intake regulation. GHRP-6 vs GHRP-2: both are non-selective GHRPs producing GH alongside cortisol and prolactin co-stimulation, but GHRP-6 is noted for more pronounced ghrelin-like appetite stimulation, while GHRP-2 produces greater GH output per unit dose in some comparative studies. Neither offers the selectivity profile of ipamorelin, which emerged from subsequent GHRP research specifically to reduce off-target hormonal effects. GHRP-6 is administered by subcutaneous injection following reconstitution with bacteriostatic water. Providers offering GHRP-class secretagogues are listed in the PeptideBase directory.

Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.

IGF-1-LR3 (Long Arg3 IGF-1) is a synthetic 83-amino-acid analog of insulin-like growth factor 1, engineered with an N-terminal 13-amino-acid extension and an Arg3 substitution that substantially reduces binding to IGF-binding proteins (IGFBPs), resulting in a biological half-life approximately 120 times longer than native IGF-1 and theoretically greater receptor availability in peripheral tissues. The reduced IGFBP affinity means a higher proportion of circulating IGF-1-LR3 remains unbound and potentially bioactive; in vitro cell proliferation studies and animal models suggest amplified anabolic signaling relative to equimolar native IGF-1, and the compound is widely used as a research reagent in cell culture for controlled IGF-1R stimulation without the confounding effects of endogenous binding protein dynamics. No human pharmacokinetic, safety, or efficacy studies of IGF-1-LR3 have been published in PubMed-indexed journals; the indexed scientific literature consists of in vitro proliferation studies, animal metabolic research, and anti-doping detection methods — a complete absence of clinical data supporting or characterizing its use in humans. IGF-1-LR3 has no FDA approval or regulatory approval in any jurisdiction; it is a research laboratory reagent and non-approved analog available through research chemical suppliers, and the complete absence of published human data means its pharmacological behavior, tissue distribution, and safety profile in humans are entirely uncharacterized. IGF-1 LR3 in research contexts: as a laboratory reagent, IGF-1-LR3 is used at nanomolar concentrations in cell culture assays to stimulate IGF-1 receptor signaling. The extended half-life (approximately 20–30 hours compared to native IGF-1's 15 minutes) is the primary reason for its use in research settings requiring sustained IGF-1R activation. In animal pharmacology studies, doses vary widely by species and model; these cannot be directly extrapolated to human dosing, and no safe or effective human dose has been established. Its extended half-life relative to native IGF-1 is also the property most frequently cited in anti-doping detection literature, where the compound has been identified in biological samples from competitive athletes. The absence of any human clinical data distinguishes IGF-1-LR3 from growth hormone secretagogues such as sermorelin, ipamorelin, or MK-677, which have documented human pharmacological profiles. Providers offering researched GH-axis peptides with clinical datasets are listed in the PeptideBase directory.